Summary:
- Slocum, Gordon & Co LLP sold all shares of Kimberly-Clark Corporation, reducing their position to zero.
- Top holdings after the filing included Procter & Gamble, NextEra Energy, and Exxon Mobil.
- Kimberly-Clark’s stock performance has been stagnant, with challenges and restructuring efforts ahead.
Article:
In a recent filing with the U.S. Securities and Exchange Commission, Slocum, Gordon & Co LLP revealed that they had sold all 20,789 shares of Kimberly-Clark Corporation during the second quarter of 2025. This move effectively reduced their position in Kimberly-Clark to zero by June 30, 2025, with an estimated transaction value of approximately $2.96 million based on the quarterly average price.Following the sale of Kimberly-Clark shares, Slocum, Gordon & Co LLP’s top holdings included Procter & Gamble, NextEra Energy, Exxon Mobil, Merck, and American Electric Power. Meanwhile, Kimberly-Clark’s stock price was noted at $131.33 as of August 18, 2025, with a 1-year price drop of 8.46% and underperformance compared to the S&P 500.
Kimberly-Clark, a leading manufacturer of personal care and tissue products, has faced challenges in recent years despite being a pandemic favorite. Its stock has experienced a decline of over 15% in the last five years, with earnings misses and a cost-sensitive consumer base impacting performance. The company is currently undergoing restructuring efforts to optimize manufacturing and focus on growth opportunities.
While Kimberly-Clark’s brands like Huggies and Kleenex are household names, factors like declining birth rates and global tariff negotiations pose challenges. The company’s restructuring aims to address these issues and position it for future success. As investors navigate these uncertainties, Kimberly-Clark’s performance and strategic moves will be closely monitored in the coming quarters.
It is important to note that the author of this article, Kristi Waterworth, does not hold any positions in the mentioned stocks. The Motley Fool, however, has positions in and recommends Merck and NextEra Energy, with a disclosure policy in place.
